Hot Stocks Overview: TransEnterix, Inc. (NYSE:TRXC), Histogenics Corporation (NASDAQ:HSGX)

stock recommendation

TransEnterix, Inc. (NYSE:TRXC)

BTIG Research Downgrades TransEnterix, Inc. (NYSE:TRXC)’s stock to Neutral with no specific Price Target. This rating was issued on 6/28/18. The stock recently closed its previous session at $2.99 by showing a percentage change of -8.28% from its previous day closing price of $3.26.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on TransEnterix, Inc. (NYSE:TRXC) in which Ladenburg Thalmann Downgrades TransEnterix, Inc. (NYSE:TRXC) to Neutral by settling a price target of $4 on 5/29/18. Stifel Nicolaus Maintains the stock to Buy on 10/30/17 by stationing a price target of $4. B. Riley FBR Downgrades the company’s stock to Neutral on 5/11/17 by setting a price target of $0.7. B. Riley FBR Initiates Coverage on TransEnterix, Inc. (NYSE:TRXC) to Buy with no specific Price Target.

TransEnterix, Inc. (NYSE:TRXC) currently has a consensus Price Target of $6.17. While some analysts have a High Price target for the stock of $6.5 and a Low Price Target of $6.

Several sell side analysts reviewed their recommendations on TransEnterix, Inc. (NYSE:TRXC) where 1 analyst have rated the stock as Strong Buy, 1 analysts said it’s a Buy, 3 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 2.5. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, TransEnterix, Inc. (NYSE:TRXC) reported its Actual EPS of $-0.06/share. The analysts offering Earnings Estimates for the company were believing that TransEnterix, Inc. (NYSE:TRXC) could bring EPS of $-0.06/share. The difference between Actual EPS and Estimated EPS was 0 Percent. Thus the company showed an Earnings Surprise of 0 Percent.

TransEnterix, Inc. (NYSE:TRXC) has a market capitalization of 626.54 Million. The stock traded with the volume of 6.9 Million shares in the last trading session. The stock touched its high share price of $6.98 on 09/25/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 02/09/18 as $1.27. The company has a 1 Year high price target of $6.17. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of -38.28%. The Moving Average SMA50 is -43.8% while SMA200 is -13.49%.

TransEnterix, Inc. (NYSE:TRXC) is currently showing its ROA (Return on Assets) of -64.9%. The Return on Investment (ROI) is at -30.5% while it’s Return on Equity (ROE) value stands at -94.7%. The stock currently shows its YTD (Year to Date) performance of 54.92 percent while its Weekly performance value is -32.35%. The Monthly and Yearly performances are -50.5 percent and 4.55 percent respectively. The Relative Volume value measured for TransEnterix, Inc. (NYSE:TRXC) is 1.06. The Average Volume (3 months) is 6.5 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. TRXC has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 6.97 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

TransEnterix Inc. designs, develops and manufactures medical-devices. It offers SPIDER(R) Surgical System, a laparoscopic surgical platform that allows intra-abdominal triangulation procedures to be performed with articulating instruments through a single site. The company is primarily focused on the development and commercialization of SurgiBot, a patient-side minimally invasive surgical robotic system. TransEnterix Inc., formerly known as SafeStitch Medical, Inc., is based in United States.

Histogenics Corporation (NASDAQ:HSGX)

BTIG Research Downgrades Histogenics Corporation (NASDAQ:HSGX)’s stock to Neutral with no specific Price Target. This rating was issued on 9/06/18. The stock recently closed its previous session at $0.78 by showing a percentage change of 4.46% from its previous day closing price of $0.75.

Price Target is basically a projection of future price of a company’s stock by the expert analysis of investment analysts or investment firms. There may be various price targets for a stock. These analysts and investment firms use various valuation methods to decide a price target for a stock.

Several investment firms issued their expert ratings on Histogenics Corporation (NASDAQ:HSGX) in which H.C. Wainwright Initiates Coverage On Histogenics Corporation (NASDAQ:HSGX) to Buy by settling a price target of $3.5 on 12/19/16. William Blair Downgrades the stock to Market Perform on 9/07/16 with no specific Price Target. BTIG Research Upgrades the company’s stock to Buy on 8/12/16 by setting a price target of $3.5. BTIG Research Downgrades Histogenics Corporation (NASDAQ:HSGX) to Neutral with no specific Price Target.

Histogenics Corporation (NASDAQ:HSGX) currently has a consensus Price Target of $2.5. While some analysts have a High Price target for the stock of $3.5 and a Low Price Target of $1.5.

Several sell side analysts reviewed their recommendations on Histogenics Corporation (NASDAQ:HSGX) where 0 analyst have rated the stock as Strong Buy, 4 analysts said it’s a Buy, 1 rated the stock as Hold, 0 analysts reported Underperform and 0 analysts gave their recommendations as Sell. (Current Month Yahoo Finance Ratings)

Zacks Investment Research also rated the stock with a value of 1.5. This scale runs from 1 to 5 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Histogenics Corporation (NASDAQ:HSGX) reported its Actual EPS of $-0.13/share. The analysts offering Earnings Estimates for the company were believing that Histogenics Corporation (NASDAQ:HSGX) could bring EPS of $-0.23/share. The difference between Actual EPS and Estimated EPS was 0.1 Percent. Thus the company showed an Earnings Surprise of 43.5 Percent.

Histogenics Corporation (NASDAQ:HSGX) has a market capitalization of 48.62 Million. The stock traded with the volume of 6.85 Million shares in the last trading session. The stock touched its high share price of $3.35 on 03/15/18 and the stock also touched its Lowest price in the last 52-weeks of trading on 10/11/18 as $0.50. The company has a 1 Year high price target of $3. The stock is currently trading with a distance of 20-Day Simple Moving Average (SMA20) of 18.98%. The Moving Average SMA50 is -31.17% while SMA200 is -64.85%.

Histogenics Corporation (NASDAQ:HSGX) is currently showing its ROA (Return on Assets) of -173.6%. The Return on Investment (ROI) is at 0% while it’s Return on Equity (ROE) value stands at 184.5%. The stock currently shows its YTD (Year to Date) performance of -61.76 percent while its Weekly performance value is 8.02%. The Monthly and Yearly performances are 40.26 percent and -63.88 percent respectively. The Relative Volume value measured for Histogenics Corporation (NASDAQ:HSGX) is 1.77. The Average Volume (3 months) is 3.86 Million.

The stock currently has its Annual Dividend of $0 and an annual Dividend Yield of 0 Percent. HSGX has P/E (Price to Earnings ttm) value of 0, Forward P/E of 0, P/C (Price to cash per share) of 4.68 and Price to Free Cash Flow (P/FCF) value of 0. The stock is showing its Operating Margin of 0 percent.

Company Profile:

Histogenics Corporation is a regenerative medicine company. It is focused on developing and commercializing products in the musculoskeletal segment. The company is developing NeoCart(R) product to provide treatment in the orthopedic space. Histogenics Corporation is headquartered in Waltham, Massachusetts.